SZSimone Zanella

Simone Zanella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simone Zanella has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Total synthesis of the complex taxane diterpene canataxpropellane

    by Fabian Schneider, Konstantin Samarin, Simone Zanella, Tanja Gaich

    Synthesis of Taxol's complicated cousin: Propellane molecules contain three rings that all share a common edge, thereby collectively resembling a propeller. Canataxpropellane, a yew-derived natural product related to the cancer drug Taxol, is unusual in that it has two different propellane motifs in its backbone. Schneider et al. report a chemical synthesis of this intricate compound in under 30 steps. Key features of the route include a Diels-Alder reaction rendered asymmetric by introduction of a chiral silyl auxiliary, followed by a photochemical cycloaddition to establish the cyclobutane core. Science , this issue p. 676


  • Open Access

    Tumor Targeting with an isoDGR–Drug Conjugate

    by Simone Zanella, Simona Angerani, Arianna Pina, Paula López Rivas, Clelia Giannini, Silvia Panzeri, Daniela Arosio, Michele Caruso, Fabio Gasparri, Ivan Fraietta, et al.

    Herein we report the first example of an isoDGR–drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αVβ3. Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val–Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αVβ3 receptor (IC50=11.0 nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti‐proliferative assays on two isogenic cancer cell lines characterized by different integrin αVβ3 expression: human glioblastoma U87 (αVβ3+) and U87 β3‐KO (αVβ3−). The isoDGR‐PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD‐PTX conjugate 4 (TI=2.4).